CD276 and bone metastasis: Because the majority of clinical mPCs progress following ADT and ARSI treatment with the retention of AR signaling, and patients often harbor bone metastases, we further tested B7H3-PBD-ADC activity against a late-stage ARPC bone metastasis model.